中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

能量代谢指标与失代偿期乙型肝炎肝硬化患者短期内自发性细菌性腹膜炎发生风险的相关性

陈秀敏 林升龙 王香梅 马华晳 张冬青 廖资渊 林明华 高海兵

引用本文:
Citation:

能量代谢指标与失代偿期乙型肝炎肝硬化患者短期内自发性细菌性腹膜炎发生风险的相关性

DOI: 10.3969/j.issn.1001-5256.2022.06.018
基金项目: 

福建省医学创新课题 (2020CXB038);

福州市科技计划项目 (2021-S-240)

伦理学声明:研究方案于2018年7月6日通过福建医科大学孟超肝胆医院伦理委员会审核批准,批号:科审2018-027-01。
利益冲突声明:本研究不存在研究者、伦理委员会、受试者及公开研究成果有关的利益冲突。
作者贡献声明:陈秀敏、林升龙和高海兵负责提出研究选题,设计研究方案,实施研究过程,起草论文;林升龙和王香梅负责统计分析;马华晳、张冬青和廖资渊负责采集和整理数据;林明华负责指导性支持,设计论文框架,修订论文,终审论文。
详细信息
    通信作者:

    高海兵,gaohb605@163.com

Association of energy metabolic markers with the short-term risk of spontaneous bacterial peritonitis in patients with decompensated hepatitis B virus-related liver cirrhosis

Research funding: 

Fujian Medical Innovation Program (2020CXB038);

Science and Technology Program of Fuzhou City (2021-S-240)

More Information
    Corresponding author: GAO Haibing, gaohb605@163.com (ORCID:0000-0002-7266-1487)
  • 摘要:   目的  探讨失代偿期乙型肝炎肝硬化(HBV-LC)患者的间接能量代谢指标与自发性细菌性腹膜炎(SBP)发生风险的相关性。  方法  回顾性分析2017年11月—2019年11月福建医科大学孟超肝胆医院收治住院的失代偿期HBV-LC患者的临床资料,比较住院后2周内发生SBP和无SBP患者的基线临床参数和能量代谢指标的差异,采用logistic多因素回归分析患者发生SBP的相关风险因素。符合正态分布的计量资料两组间比较采用t检验;非正态分布的计量资料两组间比较采用Kruskal-Wallis H秩和检验。计数资料两组间比较采用χ2检验或Fisher精确检验。绘制受试者工作特征曲线(ROC曲线)分析新建立logistic回归模型的诊断效应,以最大Youden指数对应的点为模型的截断值,采用DeLong检验比较ROC曲线下面积(AUC)。  结果  纳入失代偿期HBV-LC患者50例,住院后2周内发生SBP患者23例(46%),无SBP患者27例(54%)。SBP患者的甘油三酯、前白蛋白以及凝血酶原活动度(PTA)均显著低于无SBP患者(P值均<0.05);而SBP患者的国际标准化比值、C反应蛋白(CRP)和终末期肝病模型评分则显著高于无SBP患者(P值均<0.05)。比较两组患者的基线能量代谢指标:SBP患者的呼吸熵(RQ)和碳水化合物氧化率(CHO)均较无SBP患者低[RQ: 0.79(0.76~0.86) vs 0.85(0.79~0.91), P=0.041; CHO: 20.50%(15.25%~41.05%) vs 41.6%(22.25%~68.05%), P=0.041]。logistic多因素回归分析提示PTA为失代偿期HBV-LC患者住院期间发生SBP的独立危险因素(比值比=0.004,P=0.008),并以PTA、CRP、RQ和CHO等变量构建回归模型,模型AUC为85.0%,当曲线的Youden指数为最大值时,模型截断值为0.60,特异度为85.19%,敏感度为73.91%,模型的区分度优于CRP(AUC=74.5%, P=0.049)和PCT(AUC=56.4%, P<0.01)。  结论  失代偿期HBV-LC患者短期内发生SBP的患者能量代谢指标RQ和CHO明显降低,结合PTA、CRP和CHO/RQ比值等指标,有助于临床医师早期判断SBP的高风险患者,并加强对高风险患者的营养支持。

     

  • 图  1  新模型、CRP和PCT的ROC曲线图

    Figure  1.  The ROC curves of the new model, CRP and PCT

    表  1  基线特征比较

    Table  1.   Comparison of baseline characteristics

    指标 所有患者(n=50) SBP组(n=23) 无SBP组(n=27) 统计值 P
    性别[例(%)] 0.689
      女 7(14) 4(17) 3(11)
      男 43(86) 19(83) 24(89)
    肝衰竭[例(%)] χ2=2.7 0.103
      是 21(42) 13(57) 8(30)
      否 29(58) 10(43) 19(70)
    年龄(岁) 49.98±11.61 53.13±11.62 47.30±11.11 t=1.8 0.078
    身高(cm) 168(165~170) 165(163~170) 168(165~170) H=230.5 0.117
    体质量(kg) 62.1(55.2~72.0) 63.0(53.7~71.0) 61.0(55.9~71.9) H=304.5 0.915
    体表面积(m2) 1.73±0.17 1.71±0.16 1.74±0.18 H=-0.7 0.517
    BMI[例(%)] 0.793
      下降 5(10) 2(9) 3(11)
      正常 32(64) 14(61) 18(67)
      超重 10(20) 6(26) 4(15)
      肥胖 3(6) 1(4) 2(7)
    下载: 导出CSV

    表  2  实验室指标比较

    Table  2.   Comparison of laboratory parameters

    指标 所有患者(n=50) SBP组(n=23) 无SBP组(n=27) 统计值 P
    总胆红素(μmol/L) 124.95(43.75~274.40) 185.80(83.40~280.60) 77.70(29.30~245.45) H=403.0 0.073
    白蛋白(g/L) 33.2±5.8 31.6±5.4 34.6±5.9 t=-1.8 0.071
    前白蛋白(g/L) 55(45~88) 50(38~65) 78(51~126) H=177.5 0.010
    胆碱酯酶(U/L) 3401(2230~5029) 3120(2094~4299) 4111(2367~5396) H=256.5 0.298
    血糖(mmol/L) 5.27(4.74~7.18) 5.50(4.68~6.58) 5.22(4.84~7.28) H=311.0 0.992
    甘油三酯(mmol/L) 0.88(0.71~1.20) 0.81(0.69~0.94) 1.09(0.76~1.27) H=208.5 0.048
    总胆固醇(mmol/L) 2.94±1.19 2.69±1.15 3.15±1.20 t=-1.4 0.179
    低密度脂蛋白(mmol/L) 1.57±0.70 1.52±0.73 1.62±0.68 t=-0.5 0.600
    高密度脂蛋白(mmol/L) 0.56(0.21~0.90) 0.46(0.17~0.65) 0.74(0.29~1.04) H=216.5 0.069
    血肌酐(μmol/L) 73(63~87) 70(65~85) 73(61~88) H=306.5 0.946
    PTA(%) 0.56±0.22 0.45±0.16 0.66±0.21 t= -4.0 <0.001
    INR 1.55(1.20~2.04) 1.99(1.50~2.46) 1.25(1.12~1.67) H= 482.0 <0.001
    血红蛋白(g/L) 124.12±21.03 118.78±17.31 128.67±23.10 t=-1.7 0.091
    血小板(×109/L) 81.0(53.5~110.3) 74.0(51.5~95.0) 92.0(57.5~124.5) H=234.5 0.142
    MELD评分 16.81±6.84 19.83±6.22 14.25±6.37 t=3.1 0.003
    CRP(mg/L) 8.37(3.32~14.79) 13.42(6.82~21.44) 6.79(2.05~9.42) H=462.5 0.003
    PCT(ng/mL) 0.36(0.11~0.71) 0.55(0.08~0.76) 0.35(0.15~0.60) H=350.5 0.442
    注:PCT,降钙素原。
    下载: 导出CSV

    表  3  能量代谢指标比较

    Table  3.   Comparison of energy metabolism indices

    指标 所有患者(n=50) SBP组(n=23) 无SBP组(n=27) 统计值 P
    REE(kcal) 1 513.30±323.65 1 493.78±266.95 1 529.93±369.44 t=-0.4 0.691
    pREE((kcal) 1396(1312~1565) 1383(1259~1504) 1401(1327~1594) H=266.0 0.392
    RQ 0.82(0.78~0.89) 0.79(0.76~0.86) 0.85(0.79~0.91) H=205.0 0.041
    npRQ 0.82(0.78~0.90) 0.79(0.76~0.86) 0.85(0.79~0.91) H=210.0 0.051
    FAT(%) 49.70(28.15~65.33) 55.80(40.85~69.30) 43.80(15.35~61.40) H=385.0 0.149
    CHO(%) 31.55(18.15~52.83) 20.50(15.25~41.05) 41.60(22.25~68.05) H=205.0 0.041
    PRO(%) 15.2(8.0~22.1) 15.1(5.1~24.4) 15.5(8.4~19.3) H=302.5 0.884
    CHO/RQ 0.38(0.23~0.59) 0.26(0.20~0.48) 0.49(0.28~0.62) H=202.5 0.036
    注:pREE,预测静息能量消耗;FAT,脂肪氧化率。
    下载: 导出CSV

    表  4  logistic回归模型参数

    Table  4.   The parameters of logistic regression model

    参数 系数 比值比 95%置信区间 Z P
    截距 2.18 0.611~163.911 1.559 0.119
    PTA -5.43 0.004 0.000~0.179 -2.634 0.008
    CHO/RQ -0.93 0.396 0.011~13.843 -0.517 0.605
    CRP 0.08 1.086 1.012~1.204 1.899 0.058
    下载: 导出CSV
  • [1] Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of ascites and complications in cirrhosis[J]. J Clin Hepatol, 2017, 33(10): 1847-1863. DOI: 10.3969/j.issn.1001-5256.2017.10.003.

    中华医学会肝病学分会. 肝硬化腹水及相关并发症的诊疗指南[J]. 临床肝胆病杂志, 2017, 33(10): 1847-1863. DOI: 10.3969/j.issn.1001-5256.2017.10.003.
    [2] European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69(2): 406-460. DOI: 10.1016/j.jhep.2018.03.024.
    [3] MARCIANO S, DÍAZ JM, DIRCHWOLF M, et al. Spontaneous bacterial peritonitis in patients with cirrhosis: incidence, outcomes, and treatment strategies[J]. Hepat Med, 2019, 11: 13-22. DOI: 10.2147/HMER.S164250.
    [4] CHINNOCK B, AFARIAN H, MINNIGAN H, et al. Physician clinical impression does not rule out spontaneous bacterial peritonitis in patients undergoing emergency department paracentesis[J]. Ann Emerg Med, 2008, 52(3): 268-273. DOI: 10.1016/j.annemergmed.2008.02.016.
    [5] TANDON P, RAMAN M, MOURTZAKIS M, et al. A practical approach to nutritional screening and assessment in cirrhosis[J]. Hepatology, 2017, 65(3): 1044-1057. DOI: 10.1002/hep.29003.
    [6] LI YT, HUANG JR, PENG ML. Current status and prospects of spontaneous peritonitis in patients with cirrhosis[J]. Biomed Res Int, 2020, 2020: 3743962. DOI: 10.1155/2020/3743962.
    [7] MONTANO-LOZA AJ, MEZA-JUNCO J, PRADO CM, et al. Muscle wasting is associated with mortality in patients with cirrhosis[J]. Clin Gastroenterol Hepatol, 2012, 10(2): 166-173, 173. e1. DOI: 10.1016/j.cgh.2011.08.028.
    [8] RODRIGUES SG, BRABANDT B, STIRNIMANN G, et al. Adipopenia correlates with higher portal pressure in patients with cirrhosis[J]. Liver Int, 2019, 39(9): 1672-1681. DOI: 10.1111/liv.14175.
    [9] Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Gastroenterology, Chinese Medical Association. Clinical guidelines on nutrition in end-stage liver disease[J]. J Clin Hepatol, 2019, 35(6): 1222-1230. DOI: 10.3969/j.issn.1001-5256.2019.06.010.

    中华医学会肝病学分会, 中华医学会消化病学分会. 终末期肝病临床营养指南[J]. 临床肝胆病杂志, 2019, 35(6): 1222-1230. DOI: 10.3969/j.issn.1001-5256.2019.06.010.
    [10] Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [11] Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
    [12] TERAKURA Y, SHIRAKI M, NISHIMURA K, et al. Indirect calorimetry and anthropometry to estimate energy metabolism in patients with liver cirrhosis[J]. J Nutr Sci Vitaminol (Tokyo), 2010, 56(6): 372-379. DOI: 10.3177/jnsv.56.372.
    [13] PENG S, PLANK LD, MCCALL JL, et al. Body composition, muscle function, and energy expenditure in patients with liver cirrhosis: a comprehensive study[J]. Am J Clin Nutr, 2007, 85(5): 1257-1266. DOI: 10.1093/ajcn/85.5.1257.
    [14] PRIETO-FRÍAS C, CONCHILLO M, PAYERAS M, et al. Factors related to increased resting energy expenditure in men with liver cirrhosis[J]. Eur J Gastroenterol Hepatol, 2016, 28(2): 139-145. DOI: 10.1097/MEG.0000000000000516.
    [15] BELARMINO G, SINGER P, GONZALEZ MC, et al. Prognostic value of energy expenditure and respiratory quotient measuring in patients with liver cirrhosis[J]. Clin Nutr, 2019, 38(4): 1899-1904. DOI: 10.1016/j.clnu.2018.07.001.
    [16] de WAELE E, MALBRAIN M, SPAPEN H. Nutrition in Sepsis: A bench-to-bedside review[J]. Nutrients, 2020, 12(2): 395. DOI: 10.3390/nu12020395.
    [17] KAO CC, GUNTUPALLI KK, BANDI V, et al. Whole-body CO2 production as an index of the metabolic response to sepsis[J]. Shock, 2009, 32(1): 23-28. DOI: 10.1097/SHK.0b013e3181970f32.
    [18] GLASS C, HIPSKIND P, TSIEN C, et al. Sarcopenia and a physiologically low respiratory quotient in patients with cirrhosis: a prospective controlled study[J]. J Appl Physiol (1985), 2013, 114(5): 559-565. DOI: 10.1152/japplphysiol.01042.2012.
    [19] TAJIKA M, KATO M, MOHRI H, et al. Prognostic value of energy metabolism in patients with viral liver cirrhosis[J]. Nutrition, 2002, 18(3): 229-234. DOI: 10.1016/s0899-9007(01)00754-7.
    [20] NISHIKAWA H, ENOMOTO H, IWATA Y, et al. Prognostic significance of nonprotein respiratory quotient in patients with liver cirrhosis[J]. Medicine (Baltimore), 2017, 96(3): e5800. DOI: 10.1097/MD.0000000000005800.
    [21] LI A, MUKHOPADHYAY A. Correction to: Substrate utilization and energy expenditure pattern in sepsis by indirect calorimetry[J]. Crit Care, 2020, 24(1): 660. DOI: 10.1186/s13054-020-03391-7.
    [22] TANG L, YIN X. Diagnostic value of serum procalcitonin, C-reactive protein and neutrophil CD64 index in early diagnosis of neonatal infection with umbilical vein catheterization[J/CD]. Chin J Exp Clin Infect Dis(Electronic Edition), 2020, 14(4): 336-339. DOI: 10.3877/cma.j.issn.1674-1358.2020.04.013.

    唐磊, 尹旭. 血清降钙素原、C反应蛋白和中性粒细胞CD64指数对脐静脉置管新生儿感染早期诊断价值[J/CD]. 中华实验和临床感染病杂志(电子版), 2020, 14(4): 336-339. DOI: 10.3877/cma.j.issn.1674-1358.2020.04.013.
    [23] LI T, CHEN YY, SUN HS, et al. Application of hematology-related indexes in early diagnosis of bacterial infection of tumor patients in ICU[J]. J Jilin Univ(Med Edit), 2020, 46(4): 816-821. DOI: 10.13481/j.1671-587x.20200424.

    李铤, 陈媛媛, 孙洪帅, 等. 血液学相关指标在ICU肿瘤患者细菌感染早期诊断中的应用[J]. 吉林大学学报(医学版), 2020, 46(4): 816-821. DOI: 10.13481/j.1671-587x.20200424.
    [24] METWALLY K, FOUAD T, ASSEM M, et al. Predictors of spontaneous bacterial peritonitis in patients with cirrhotic ascites[J]. J Clin Transl Hepatol, 2018, 6(4): 372-376. DOI: 10.14218/JCTH.2018.00001.
    [25] ABDEL-RAZIK A, MOUSA N, ELHAMMADY D, et al. Ascitic fluid calprotectin and serum procalcitonin as accurate diagnostic markers for spontaneous bacterial peritonitis[J]. Gut Liver, 2016, 10(4): 624-631. DOI: 10.5009/gnl15120.
    [26] MIKUŁA T, SAPUŁA M, JABŁOŃSKA J, et al. Significance of heparin-binding protein and D-dimers in the early diagnosis of spontaneous bacterial peritonitis[J]. Mediators Inflamm, 2018, 2018: 1969108. DOI: 10.1155/2018/1969108.
    [27] SHEN HX, LOU XP, CHANG XW, et al. Risk factors for spontaneous bacterial peritonitis in cirrhotic patients: A meta analysis[J]. World Chin J Dig, 2016, 24(12): 1903-1909. DOI: 10.11569/wcjd.v24.i12.1903.

    申红霞, 娄小平, 苌新伟, 等. 肝硬化患者自发性细菌性腹膜炎危险因素的Meta分析[J]. 世界华人消化杂志, 2016, 24(12): 1903-1909. DOI: 10.11569/wcjd.v24.i12.1903.
  • 加载中
图(1) / 表(4)
计量
  • 文章访问数:  346
  • HTML全文浏览量:  107
  • PDF下载量:  44
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-11-15
  • 录用日期:  2021-12-27
  • 出版日期:  2022-06-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回